Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases (LIVERT(W)OHEAL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03488953 |
Recruitment Status : Unknown
Verified March 2022 by Falk Rauchfuß, Jena University Hospital.
Recruitment status was: Recruiting
First Posted : April 5, 2018
Last Update Posted : March 29, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Nearly one third of patients with colorectal cancer develop liver metastases. It is well known that the achievement of a R0-situation is one of the most important factors for a positive long-term outcome. Despite further advantages in multimodal treatment concepts, only 20 - 30 % of the patients with metastases can be resected in curative intention.
Recent studies, especially from Norway, have shown that liver transplantation might be a feasible option in well selected patients since the complete hepatectomy with subsequent liver transplantation can be an option for the achievement of a R0 situation.
In this study, we pursue the strategy of two-stage hepatectomy combined with a left-lateral living donor liver transplantation.
Inclusion criteria are as follows: non-resectable liver metastases of a primary colorectal carcinoma with an assumed portal-venous drainage of the tumor and at least a "stable disease" after a period of eight weeks systemic chemotherapy. Patients are excluded from the study if there is an extrahepatic tumor burden (with the exception of resectable lung metastases) or if the patient is not suitable for liver transplantation due to co-morbidities.
The transplantation itself will be undertaken as a living donor liver transplantation where the left lateral liver lobe (liver segments 2 & 3) from a healthy volunteer donor will serve as graft. Prior transplantation, a left hemihepatectomy in the recipient is performed and the left lateral graft will be transplanted in this position. At the end of the transplantation procedure, the right portal vein will be closed to induce a rapid growth of the graft. The second step, and therefore the completion of the operation is performed after a growth period of the transplanted left-lateral lobe: in this procedure, the right hemi-liver of the recipient will be removed and the patient is supposed to be free of tumor at this point in time.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Metastatic Liver Metastases | Procedure: Living donor liver transplantation with two-staged hepatectomy. | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases |
Actual Study Start Date : | April 10, 2018 |
Estimated Primary Completion Date : | June 30, 2023 |
Estimated Study Completion Date : | December 15, 2023 |
Arm | Intervention/treatment |
---|---|
Transplantation Arm |
Procedure: Living donor liver transplantation with two-staged hepatectomy.
Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor. |
- Overall survival three years after 2nd-stage of hepatectomy [ Time Frame: 3 years ]Overall survival three years after 2nd-stage of hepatectomy
- Disease-free survival three years after 2nd-stage of hepatectomy [ Time Frame: 3 years ]Disease-free survival three years after 2nd-stage of hepatectomy
- Morbidity of the recipient [ Time Frame: 3 years ]all complications > grade IIIa according to the Clavien-Dindo classification
- Morbidity of the donor [ Time Frame: 3 years ]all complications > grade IIIa according to the Clavien-Dindo classification
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with irresectable colorectal liver metastases without extrahepatic tumor burden, except resectable pulmonary metastases
- stable disease or regression after at least eight weeks of systemic chemotherapy
Exclusion Criteria:
- comorbidities precluding liver transplantation
- extrahepatic tumor spread, except resectable pulmonary metastases
- progression during chemotherapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03488953
Contact: Falk Rauchfuss, M.D., M.Sc. | 004936419322601 | Falk.Rauchfuss@med.uni-jena.de | |
Contact: Ulrike McCaulley, Study Nurse | 004936419322694 | Ulrike.McCaulley@med.uni-jena.de |
Germany | |
Jena University Hospital | Recruiting |
Jena, Germany, 07747 | |
Contact: Falk Rauchfuss, M.D., M.Sc. 004936419322601 Falk.Rauchfuss@med.uni-jena.de | |
Contact: Utz Settmacher, M.D. 004936419322601 Utz.Settmacher@med.uni-jena.de | |
University Hospital Tübingen | Recruiting |
Tübingen, Germany, 72076 | |
Contact: Alfred Königsrainer, M.D. 004970712986620 Alfred.Koenigsrainer@med.uni-tuebingen.de | |
Contact: Silvio Nadalin, M.D. 004970712986600 silvio.nadalin@med.uni-tuebingen.de |
Responsible Party: | Falk Rauchfuß, Senior Surgeon, Jena University Hospital |
ClinicalTrials.gov Identifier: | NCT03488953 |
Other Study ID Numbers: |
AVG-001 |
First Posted: | April 5, 2018 Key Record Dates |
Last Update Posted: | March 29, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Liver transplantation Two-stage hepatectomy Living donor liver transplantation |
Neoplasm Metastasis Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Neoplastic Processes Pathologic Processes Liver Diseases |